CoChat

Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial

Open access
Gerstein, Hertzel C, Miller, Michael E, Ismail-Beigi, Faramarz, Largay, Joe, McDonald, Charlotte, Lochnan, Heather A, Booth, Gillian L · 2014 · The Lancet
Cited by 151

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Background The possibility that hyperglycemia accounts for the 2–3 fold higher risk of ischemic heart disease (IHD) in type 2 diabetes was explored by assessing the effect of intensive glucose lowering on IHD in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Methods 10,251 people (mean age = 62) with type 2 diabetes (mean duration = 10 years, mean A1c = 8.3%) were allocated to intensive or standard glycemic control targeting an A1c <6% or 7–7.9% respectively. This intervention’s effect on IHD (fatal or non-fatal myocardial infarction, coronary revascularization, unstable angina, and new angina) was assessed during a mean active treatment period of 3.7 years followed by an additional 1.2 years. Results Fewer participants allocated to the intensive versus standard care group experienced a myocardial infarction during both active treatment (HR = 0.80; 95% CI 0.67 – 0.96; P = 0.015) and full (active and additional) follow-up (HR = 0.84; 95% CI 0.72 – 0.97; P = 0.02). Similar findings were observed for a composite IHD outcome of myocardial infarction, coronary revascularization or unstable angina (HR = 0.89; 95% CI 0.79–0.99 and HR = 0.87; 95% CI 0.79 – 0.96 during active treatment and full follow-up respectively)and for coronary revascularization (HR = 0.84; 95% CI 0.75–0.94), and unstable angina (HR = 0.81; 95% CI 0.67–0.97) during full follow-up. Adding A1C levels achieved during active treatment attenuated the significant hazard ratios to neutrality. Conclusions Glucose elevation is a modifiable risk factor for IHD in middle aged people with type 2 diabetes and other IHD risk factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)60611-5

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 151

Metadata

Authors
Gerstein, H. C., Miller, M. E., Ismail-Beigi, F., Largay, J., McDonald, C., Lochnan, H. A., & Booth, G. L.
Venue
The Lancet
Publisher
Elsevier BV
Published
2014-11
Volume
384
Issue
9958
Pages
1936-1941
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2123955086
Cited by
151
References
13
FWCI
17.71
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. https://app.cochat.ai/papers/10.1016/s0140-6736(14)60611-5
The paper
Gerstein, H. C., Miller, M. E., Ismail-Beigi, F., Largay, J., McDonald, C., Lochnan, H. A., & Booth, G. L. (2014). Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. The Lancet. https://doi.org/10.1016/s0140-6736(14)60611-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.